Evaxion A/SEVAXEarnings & Financial Report
Evaxion A/S is a Danish clinical-stage biotechnology company that leverages proprietary artificial intelligence platforms to develop targeted immunotherapies. Its core pipeline includes personalized cancer vaccines, off-the-shelf immuno-oncology treatments, and novel infectious disease therapies, advancing programs through partnerships with global pharmaceutical stakeholders.
Revenue
$0
Gross Profit
N/A
Operating Profit
$-5.7M
Net Profit
$-5.7M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.21
Evaxion A/S Q2 2023 Financial Summary
Evaxion A/S reported revenue of $0 for Q2 2023, with a net profit of $-5.7M (down 19.2% YoY) (N/A margin). Cost of goods sold was N/A.
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-5.7M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q2 2023 |
Evaxion A/S Quarterly Revenue & Net Profit History
Evaxion A/S results over the last 3 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q2 2025 | $37.0K | -76.0% | $-4.8M | -13056.8% |
| Q2 2024 | $154.0K | — | $-6.2M | -4024.7% |
| Q2 2023 | $0 | — | $-5.7M | N/A |
Income Statement
| Q2 2023 | Q2 2024 | Q2 2025 | |
|---|---|---|---|
| Revenue | $0 | $154000 | $37000 |
| YoY Growth | N/A | N/A | -76.0% |
Balance Sheet
| Q2 2023 | Q2 2024 | Q2 2025 | |
|---|---|---|---|
| Assets | $16.8M | $15.2M | $22.4M |
| Liabilities | $14.2M | $14.0M | $16.2M |
| Equity | $2.5M | $1.3M | $6.2M |